Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 68

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 68
---
 insufficient to invalidate the claim if first
presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims
that would not have been invalidated if first challenged by the third party as a defendant in a district court action. An unfavorable
outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to
license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially
reasonable terms.

Even if resolved in our favor,
litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could
distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial
resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our
ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of
litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.
If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of
our common shares.

In addition, if our product
candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims
against our licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for
any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation
on behalf of licensees and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to
pay damages on behalf of those parties or may be required to obtain licenses for the products they use.

Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental